T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
Status:
NOT_YET_RECRUITING
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Neratinib in HER2-positive breast cancer with brain metastasis